Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-074665
Filing Date
2025-05-19
Accepted
2025-05-19 18:32:48
Documents
1
Period of Report
2025-05-15

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 5433
  Complete submission text file 0000950170-25-074665.txt   6850
Mailing Address C/O OREXIGEN THERAPEUTICS, INC. 3344 N TORREY PINES CT, #200 LA JOLLA CA 92037
Business Address
NARACHI MICHAEL (Reporting) CIK: 0001380022 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36276 | Film No.: 25965515

Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Issuer) CIK: 0001515673 (see all company filings)

EIN.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)